carnitine has been researched along with Liver Failure, Acute in 6 studies
Liver Failure, Acute: A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF)." | 2.82 | Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. ( Aithal, GP; Alvarez-Alvarez, I; Andrade, RJ; Arikan, C; Atallah, E; Lucena, MI; Medina-Caliz, I; Niu, H, 2022) |
| "The etiology of acute liver failure in children is unknown in a large number of cases." | 1.33 | Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis. ( Bucuvalas, J; Emre, S; Gondolesi, G; Hynan, LS; Magid, M; Morotti, R; Narkewicz, M; Rinaldo, P; Shneider, BL; Squires, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, S | 1 |
| Kumar, K | 1 |
| Malhotra, S | 1 |
| Sibal, A | 1 |
| Niu, H | 1 |
| Atallah, E | 1 |
| Alvarez-Alvarez, I | 1 |
| Medina-Caliz, I | 1 |
| Aithal, GP | 1 |
| Arikan, C | 1 |
| Andrade, RJ | 1 |
| Lucena, MI | 1 |
| Ganai, AA | 1 |
| Jahan, S | 1 |
| Ahad, A | 1 |
| Abdin, MZ | 1 |
| Farooqi, H | 1 |
| Sood, V | 1 |
| Rawat, D | 1 |
| Khanna, R | 1 |
| Sharma, S | 1 |
| Gupta, PK | 1 |
| Alam, S | 1 |
| Sarin, SK | 1 |
| Shneider, BL | 1 |
| Rinaldo, P | 1 |
| Emre, S | 1 |
| Bucuvalas, J | 1 |
| Squires, R | 1 |
| Narkewicz, M | 1 |
| Gondolesi, G | 1 |
| Magid, M | 1 |
| Morotti, R | 1 |
| Hynan, LS | 1 |
| Nowaczyk, MJ | 1 |
| Whelan, D | 1 |
| Hill, RE | 1 |
| Clarke, JT | 1 |
| Pollitt, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Group to Study Acute Liver Failure in Children[NCT00986648] | 158 participants (Actual) | Observational | 2000-01-31 | Completed | |||
| A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.[NCT00248625] | Phase 3 | 184 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00248625)
Timeframe: Within 1 year of randomization
| Intervention | percentage of participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 45 |
| Placebo | 35 |
(NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | Participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 20 |
| Placebo | 21 |
(NCT00248625)
Timeframe: Randomization to hospital discharge
| Intervention | days (Median) |
|---|---|
| N-acetylcysteine (NAC) | 103 |
| Placebo | 21 |
Survival without liver transplantation (NCT00248625)
Timeframe: One year following randomization
| Intervention | participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 33 |
| Placebo | 49 |
Spontaneous survival without transplant plus survival following transplantation (NCT00248625)
Timeframe: One year following randomization
| Intervention | Participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 68 |
| Placebo | 76 |
The length of ICU stay was categorized as number of days in ICU within 7 days of randomization, unless participant either died or received an LTx within this time period. Special categories were created for these cases. (NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 days | 1 day | 2 days | 3 days | 4 days | 5 days | 6 days | 7 days | underwent LTx w/i 7 days of randomization | died w/o LTx w/i 7 days of randomization | |
| N-acetylcysteine (NAC) | 29 | 3 | 3 | 2 | 1 | 4 | 5 | 9 | 28 | 8 |
| Placebo | 34 | 4 | 4 | 0 | 3 | 3 | 3 | 14 | 22 | 5 |
West Haven Criteria for hepatic encephalopathy (Grade 0 - IV ) is used for participants > 3 year of age. Coma grade IV indicates a participant who is comatose , with no reflexes, is decerebrate and has abnormal EEG changes with very slow delta activity. For participants less than 3 years the Whittington Scale was used. The Whittington scale does not use EEG changes and has only 3 levels, early (grades I and II), Mid (III) with somnolence, stupor, combativeness and Late (IV) for participants who are comatose with absent reflexes and decerebrate or decorticate posturing. (NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 | I | II | III | IV | |
| N-acetylcysteine (NAC) | 28 | 16 | 20 | 15 | 11 |
| Placebo | 27 | 21 | 19 | 17 | 6 |
(NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | |
| N-acetylcysteine (NAC) | 44 | 21 | 15 | 11 | 1 |
| Placebo | 46 | 23 | 12 | 8 | 3 |
1 review available for carnitine and Liver Failure, Acute
| Article | Year |
|---|---|
Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adrenal Cortex Hormones; Adult; Carnitine; Chemical and D | 2022 |
5 other studies available for carnitine and Liver Failure, Acute
| Article | Year |
|---|---|
Rare case of primary carnitine deficiency presenting as acute liver failure.
Topics: Adult; Cardiomyopathies; Carnitine; Child; Child, Preschool; Fatty Acids; Humans; Hyperammonemia; Li | 2022 |
Glycine propionyl l-carnitine attenuates d-Galactosamine induced fulminant hepatic failure in wistar rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Ataxia Telangiectasia Mutated Proteins; | 2014 |
Study of Carnitine/Acylcarnitine and Amino Acid Profile in Children and Adults With Acute Liver Failure.
Topics: Adolescent; Adult; Amino Acids; Biomarkers; Carnitine; Carnitine O-Palmitoyltransferase; Child; Chil | 2017 |
Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis.
Topics: Bile; Carnitine; Case-Control Studies; Child; Esterification; Humans; Liver; Liver Failure, Acute; L | 2005 |
Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis.
Topics: Bile; Carnitine; Case-Control Studies; Child; Esterification; Humans; Liver; Liver Failure, Acute; L | 2005 |
Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis.
Topics: Bile; Carnitine; Case-Control Studies; Child; Esterification; Humans; Liver; Liver Failure, Acute; L | 2005 |
Abnormal concentrations of esterified carnitine in bile: a feature of pediatric acute liver failure with poor prognosis.
Topics: Bile; Carnitine; Case-Control Studies; Child; Esterification; Humans; Liver; Liver Failure, Acute; L | 2005 |
Long-chain hydroxydicarboxylic aciduria, carnitine depletion and acetaminophen exposure.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetaminophen; Analgesics, Non-Narcotic; Carnitine; Fatty Acids; H | 2000 |